Create your personal agenda –check the favourite icon
Opening keynote presentation: Integrated Pandemic Preparedness
Keynotes
- How vaccines, monoclonals, direct acting antiviral, agents targeting host factors have essential roles in mounting a broad, response to future pandemics
- The need to develop and validate assays for detection of infection and measurement of immunity
Panel: HIV – how can we end the epidemic?
Keynotes
- How is new research bringing the goal of a cure within reach?
- HIV Vaccine, antibody, and antiviral landscape
- Merits / potential of different approaches – mRNA, bNAbs, LAAV, pre-exposure prophylaxis, prophylactic vs therapeutic vaccines
- To achieve success must reach all those disproportionately affected - How can PPP help to achieve this?
Pervin Anklesaria, Deputy Director, The Bill & Melinda Gates Foundation
Defining immune fitness / immune health and its implications for ID & Cancer
Keynotes
- How do we define immune fitness / immune health – progress towards human immunome
- How are we studying this at a systems level?
- How do vaccines positively impact immune fitness?
- Defining tumor archetypes – what common immunological features contribute to better response rates
Exhibition & Partnering Break
Keynotes
- Tea, Coffee and Refreshments served in the exhibition area
- One-to-one networking meetings, Poster Presentations
How can partnering with federal labs help your business?
Interactive Roundtables
How can we utilize mRNA technology to develop next generation therapeutics?
Interactive Roundtables
Ariel Weinberger, Chief Executive Officer, Autonomous
How to effectively tailor prevention and treatment strategies to pediatric populations?
Interactive Roundtables
Dr Barbara Rath, Co-founder & Chair, Vienna Vaccine Safety Initiative; Chair, ISIRV Epi Group, Board Member, ISIRV & ESCMID/ESGREV, Vienna Vaccine Safety Initiative
The future of vaccine trial sites post-COVID
Interactive Roundtables
Exhibition & Partnering Break
Keynotes
- Lunch served in exhibition area
- One-to-one networking meetings, Poster Presentations
Chair’s opening remarks
WVIC - ID Vaccines
Safety & efficacy updates of Janssen COVID-19 vaccine
WVIC - ID Vaccines
Panel: Understanding the TME; what’s left to learn
WVIC - Immune Monitoring
- Systems biology approaches to studying the TME – what have we learnt that we didn’t know before?
- How can we apply proteomics to the TME – how is this informing multiple targets?
The Centers for Research in Emerging Infectious Diseases (CREID) Network: Research Integrated Surveillance and Monitoring
WAC - Emerging & Reemerging Diseases
Oral COVID-19 vaccine ph II trials
WVIC - ID Vaccines
Kick and kill approach to HIV treatment
WAC - HIV
Applying machine learning for antiviral drug discovery
WAC - Emerging & Reemerging Diseases
SARS-CoV-2 Vaccine design to broaden effector immune responses
WVIC - ID Vaccines
Progress of therapies to overcome suppression in the TME
WVIC - Immune Monitoring
Using nanocrystal prodrugs as ultra-long-acting chemical treatment for HIV
WAC - HIV
Dr Howard Gendelman, Co-founder, Exavir Therapeutics
Targeted Protein Degradation–A novel approach to combat viral pathogens
WAC - Emerging & Reemerging Diseases
Dr Priscilla Yang, Professor, Stanford University School of Medicine (USA)
A new vaccine platform for emerging virus threats such as SARS-2, HIV, and RSV
WVIC - ID Vaccines
Glycoconjugate approaches for evoking antibodies to sugars on HIV-1
WAC - HIV
Fleximers–using unique nucleosides as a flexible approach to antiviral treatment
WAC - Emerging & Reemerging Diseases
Exhibition & Partnering Break
Keynotes
- Tea, Coffee and Refreshments served in the exhibition area
- One-to-one networking meetings, Poster Presentations
Novel Checkpoint Inhibitor Combination Vaccines (PD-1, PD-L1, CTLA-4, TIGIT, LAG3)
WVIC - Cancer Immunotherapy
Preventing HIV Drug Resistance to Current and Future Antiretroviral Treatment Regimens
WAC - HIV
Dr Robert Shafer, Professor of Medicine-Infectious Diseases, Stanford University School of Medicine (USA)
Tackling Marburg virus strains with humanized mAbs
WAC - Emerging & Reemerging Diseases
Improving clinical trial recruitment
WVIC - ID Vaccines
A novel platform for early diagnosis & predicting responses to immune checkpoint inhibitor treatment
WVIC - Immune Monitoring
Versamune t-cell activating platform for HPV related cancers
WVIC - Cancer Immunotherapy
Are long-acting ARTs the future of HIV prevention and treatment?
WAC - HIV
- How can we improve the half-life of long-acting ARTs?
- How can we enhance the uptake/usage of long-acting formulations?
- What are the implementation challenges for therapies?
- What are the key policy issues for these types of therapies?
- Why can long-acting injectable therapies be difficult to access in LMIC?
A repurposing antiviral solution for the prevention and treatment of Dengue
WAC - Emerging & Reemerging Diseases
David Foster, Chief Executive Officer, Island Pharmaceuticals
7HP349, an integrin agonist to overcome resistance to immune checkpoint blockade
WVIC - Cancer Immunotherapy
Structural mapping of the humoral immune response to the Lassa virus glycoprotein
WAC - Emerging & Reemerging Diseases
How to moonshot clinical trial diversity
WVIC - ID Vaccines
Studies informing mechanisms of resistance in oncology
WVIC - Immune Monitoring
Developing an antiviral solution for Zika
WAC - Emerging & Reemerging Diseases
Create your personal agenda –check the favourite icon
Global Health Goals – can we get back on track?
WVIC - Plenary
- How has the pandemic affected the status of the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases?
- GSK - Focus on malaria (inc. salmonela / shigella?) – how will malaria vaccines be implemented?
- HDT - TB and what went wrong? Next steps for TB vaccines.
- Partnerships to achieve these goals
Panel: What is the future of COVID-19 therapeutics?
WAC - Plenary
- What are the key areas of focus for 2023 and onwards?
- What novel therapies are being investigated?
- Is there a particular part of the SARS-CoV-2 infection cycle being targeted?
- Is there a silver bullet out there and what would it look like?
- How to ensure therapeutic interventions are easily accessible?
- How will the current and future COVID-19 therapeutics be used in the case of a new outbreak?
Dr Robert Jordan, Senior Program Officer, Bill & Melinda Gates Foundation
Pei-Yong Shi, Kempner Professor Of Human Genetics, University of Texas Medical Branch
Meghan Pennini, Director of Therapeutics H-CORE, HHS
Dr Jay Grobler, Associate Vice President Infectious Disease and Vaccines, Merck And Company
Challenges & opportunities in moving immuno-oncology drugs into earlier stages
WVIC - Plenary
- What are the challenges that need to be overcome before we can move immunotherapies into earlier stages?
- What is effect of moving earlier in moving into adjuvant/neoadjuvant space? The need to understand progression much earlier in disease.
- What are our current assumptions – what data do we need to pressure test them? How do we collect data? What data do we need?
Panel: Overcoming obstacles in developing therapeutics for neglected and emerging diseases
WAC - Plenary
- What are the challenges in designing effective clinical trials for these diseases?
- What role do platform trials play?
- What are the key regulatory issues?
- How would a collaborative nature between researchers and regulatory help with development?
- Why is funding an issue? What can be done to combat this issue?
- How to react most efficiently to unexpected disease surges (e.g Monkeypox outbreak)
Mara Kreishman-Deitrick, Deputy Commander, United States Army Medical Material Development Activity
Nancy Sullivan, Senior Investigator and Chief of the Biodefense Research Section, NIH
Dr Phil Gomez, Chief Executive Officer, SIGA Technologies, Inc.
Exhibition & Partnering Break
Keynotes
- Tea, Coffee and Refreshments served in the exhibition area
- One-to-one networking meetings, Poster Presentations
Panel: Research & development goals for influenza vaccines
WVIC - ID Vaccines
- What is the status of the influenza vaccine R&D landscape?
- What areas of R&D are we focusing on to improve influenza vaccines?
- Strategic goals for seasonal vs universal flu vaccines
- Recent milestones achieved and gaps to address
- What tools do we need to inform policy, and preparedness planning?
- Pivoting to new manufacturing platforms to ensure faster response – what are the challenges
Recent studies informing our understanding of SARS-CoV-2 Immunity * Title TBC
WVIC - Immune Monitoring
Understanding the molecular biology of COVID
WAC - COVID-19
SARS-CoV-2 Biology and Countermeasure Development
WAC - COVID-19
Pei-Yong Shi, Kempner Professor Of Human Genetics, University of Texas Medical Branch
AI driven automated viral infectivity assay to expedite antiviral drug discovery
WAC - Delivery & Technology
Personal dendritic cell vaccines for cancer and covid-19
WVIC - Cancer Immunotherapy
Structure-based drug design against SARS-CoV-2 main protease using X-rays, neutrons and computation
WAC - COVID-19
Pathological modeling and control system for optimizing antivirals for COVID-19 and beyond
WAC - Delivery & Technology
Invariable regions – a better universal flu target
WVIC - ID Vaccines
Individualized Neoantigen Immunotherapy in early stage and advanced solid tumors
WVIC - Cancer Immunotherapy
Development of fully human monoclonal antibodies against SARS-CoV2 using peripheral B-cells from COVID-19 survivors
WAC - COVID-19
Exhibition & Partnering Break
Keynotes
- Tea, Coffee and Refreshments served in the exhibition area
- One-to-one networking meetings, Poster Presentations
Showcase 1: Driven by personal experience: Discovery and development of broad-spectrum antiviral agents against respiratory track viruses
WAC - COVID-19
Showcase 2: Next generation RNAi therapy to treat COVID-19 and other respiratory diseases
WAC - COVID-19
Inhaled IFN-β (SNG001) for the treatment of COVID-19 and other severe viral lung infections
WAC - Delivery & Technology
Phillip Monk, Chief Scientific Officer, Synairgen Research Ltd
Showcase 3: Rapid virus clearance by a novel 3CL protease inhibitor in treatment of COVID-19
WAC - COVID-19
LUNAR – Flu & Covid-19 Vaccines
WVIC - ID Vaccines
Enhancing delivery via Thin Film Freezing technology for inhalable antivirals
WAC - Delivery & Technology
Showcase 6: Broadly acting cathepsins inhibitor against omicron and other variants of concern
WAC - COVID-19
Exhibition & Partnering Break
Keynotes
- Tea, Coffee and Refreshments served in the exhibition area
- One-to-one networking meetings, Poster Presentations
Developing broad-spectrum influenza vaccines against pandemic threats
WVIC - ID Vaccines
Plug-and-play nanoparticle vaccine platform to target HIV, RSV, Ebola and SARs-CoV-2
WVIC - Immune Monitoring
Treating COVID-19 in Pregnancy – The COVID-19 International Drug Pregnancy Registry (COVID-PR)
WAC - COVID-19
Pandemic Antiviral Discovery (PAD) initiative–Catalysing antiviral discovery and development
WAC - COVID-19
Dr Robert Jordan, Senior Program Officer, Bill & Melinda Gates Foundation
Cellular Nanosponges as an Emerging Antiviral Technology
WAC - Delivery & Technology
Create your personal agenda –check the favourite icon
Accelerating innovation –leveraging partnerships and collaborations to advance solutions to ID & Cancer
WVIC - Plenary
- What are the advantages of partnering with big pharma, federal labs, accelerators, foundations and private investors?
- What are their programmatic interests of the players involved in getting technologies to market?
- What emerging technologies are those in charge of partnering and collaboration most excited about?
- How can you position yourself optimally to get your tech noticed?
Panel: Therapeutic approaches to pandemic preparedness
WAC - Plenary
- Prediction–Predicting the next viral threat and developing a drug with a specific target
- Broad-spectrum–Developing drugs that work broadly across many stains/viruses
- Platforms–Warp speed platforms to develop therapeutics once a threat appears
- What are the advantages and disadvantages of each approach?
Dr Peter Daszak, President, Ecohealth Alliance Inc.
BRUNCH - Exhibition & Partnering Break
Keynotes
- Tea, Coffee and Refreshments served in the exhibition area
- One-to-one networking meetings, Poster Presentations
Chair’s opening remarks
WAC - Hepatitis
Development of two vaccine candidates implementing proprietary protective antigens against Streptococcus pneumoniae (MVX01) and Clostridioides difficile (MVX02)
WVIC - ID Vaccines
How can an Intellectual Property International Consortium (IPIC) benefit small biotechs?
WVIC - New Technology
Developing immune cell ligands as a treatment strategy for Influenza
WAC - Respiratory Viruses
Bacterial structural vaccinology and novel target delivery
WVIC - ID Vaccines
How are investors thinking about biopharma stocks?
WVIC - New Technology
B-Tech vector platform for development of next gen Pertussis and TB vaccines
WVIC - ID Vaccines
Showcase 1: A new approach to therapeutic cancer vaccines
WVIC - New Technology
Novel broad-spectrum influenza A PB2 inhibitor: clinical update
WAC - Respiratory Viruses
Progress towards GAS and Periodontitis vaccines
WVIC - ID Vaccines
Showcase 2: Early development of Smallpox & Monkey Pox Vaccines
WVIC - New Technology
Neutralizing Staphylococcus aureus virulence for vaccination and immunotherapy
WVIC - ID Vaccines
Subviral particle clearance and transaminase flares – roles in functional cure.
WAC - Hepatitis
Exhibition & Partnering Break
Keynotes
- Tea, Coffee and Refreshments served in the exhibition area
- One-to-one networking meetings, Poster Presentations
The role of influenza antivirals–How can we reduce morbidity and mortality at the individual and population level?
WAC - Respiratory Viruses
Protocol Interferon Lambda–First oral Antiviral for Hepatitis D
WAC - Hepatitis
Showcase 5: Engineering a novel SARS-CoV2 B-cell epitope vaccine and investigation in transgenic K18-hACE2 mice
WVIC - New Technology
Joint Closing Keynote Plenary Session - Leveraging genetic insights to identify novel targets for immune-based diseases
Keynotes
- How are data driven approaches being used for vaccine discovery / novel drugs in oncology?
last published: 03/Aug/22 12:15 GMT
Password must meet the following requirements:
- At least one letter
- At least one capital letter
- At least one number
- Be at least 6 characters
Carl Dieffenbach, Director, Division of AIDS,
NIAID/NIH
Dr. Carl W. Dieffenbach is the Director of the Division of AIDS at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. Under his leadership, the Division supports a global research portfolio to advance biological knowledge of HIV/AIDS, its related...
Carl Dieffenbach, Director, Division of AIDS,
NIAID/NIH
Dr. Carl W. Dieffenbach is the Director of the Division of AIDS at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. Under his leadership, the Division supports a global research portfolio to advance biological knowledge of HIV/AIDS, its related...
Brett Leav, Head, Clinical Development, Public Health Vaccines,
Moderna
Brett Leav, MD is Head of Clinical Development for Public Health Vaccines at Moderna. He was responsible for overseeing the Moderna COVID-19 vaccine clinical program in adults and children and now leads development of other vaccines to prevent intractable public health challenges, including...
Max Lataillade, Vice President, Head of Global Research Strategy,
ViiV Healthcare
Max Lataillade VP Head of global Research Strategy, is responsible for global research and development strategy for the HIV pipeline at ViiV Healthcare, the only company 100% dedicated to HIV. He oversees end-to-end R&D activities for all novel HIV pipeline programs designed to address key...
William Schief, Professor, Department Of Immunology And Microbiology,
The Scripps Research Institute
William Schief Dr. William Schief is a Professor in the Immunology and Microbial Science Department at The Scripps Research Institute in La Jolla, CA, Director for Vaccine Design at the International AIDS Vaccine Initiative (IAVI), and an Associate Member of the Ragon Institute of MGH, MIT and...
Michael Salgaller, Supervisor, Invention Development And Marketing Unit,
National Cancer Institute - NIH
Experienced biopharma and life sciences senior manager with strong and successful background in technology development, entrepreneurship, business development, strategic planning, clinical and medical affairs, R&D, and capital formation.
William Smith, PI/Chief Executive Officer,
Alliance for Multispecialty Research LLC
Dr. William Smith is the Founder, President, and Principal Investigator of VRG and NOCCR, the AMR centers in Knoxville, TN and New Orleans, LA. He is also one of the original founders of AMR. Dr. Smith is board certified in Internal Medicine, Critical Care Medicine, Nephrology and Cardiology. He...
Michael Mowatt, Director, Technology Transfer And Intellectual Property Office,
National Institute of Health - NIAID
Since 2001 Dr. Mowatt has directed the technology transfer program at the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH). His staff of fifty talented and experienced professionals support of the mission of NIAID by facilitating...
Jerald Sadoff, Senior Advisor Vaccine Development,
Janssen Vaccines & Prevention B.V.
Dr. Jerald C. Sadoff is currently the Head of Early Development of the Crucell Vaccine Institute which is the Center of Excellence for Vaccine Development for Johnson & Johnson Companies Worldwide. Dr. Sadoff has spent his entire career developing vaccines against a large number of...
Sara Woodson, Program Officer,
NIH/NIAID
Sara E. Woodson, PhD is virologist and expert in emerging and re-emerging viral diseases. She is currently a Team Lead & Program Officer for the Centers for Research in Emerging Infectious Diseases (CREID) Network program within the Translational Research Section of the Virology Branch in the...
Sean Tucker, CSO,
Vaxart
Dr. Tucker completed his doctoral degree in Immunology at the University of Washington. Dr. Tucker is the Chief Scientific Officer and Vice President for Research at Vaxart, Inc, a company focused on mucosal vaccine delivery. He has published several papers in immunology and served as a grant...
Dr Jocelyn Kim, Assistant Professor,
University of California, Los Angeles
Dr. Jocelyn Kim is currently an Assistant Professor at UCLA. She received her undergraduate and medical degrees from the University of Michigan, Ann Arbor. She completed her internal medicine residency at Johns Hopkins Hospital in Baltimore, Maryland. Her clinical infectious disease fellowship was...
Ana Puhl, Senior Research Scientist,
Collaborations Pharmaceuticals
I am Senior Scientist at Collaborations Pharmaceuticals. I joined the company in 2018 and I am involved in drug discovery projects for rare genetic diseases, neglected diseases and antiviral research. At Collaborations, I am responsible for leading, managing and executing R&D projects in...
Mark Newman, CSO,
GeoVax, Inc.
Dr. Newman has more than 30 years’ experience in the biotechnology sector serving in senior management roles at GeoVax (Atlanta, GA), PaxVax (San Diego, CA), Pharmexa (Horsholm, Denmark), Epimmune (San Diego, CA), Vaxcel (Atlanta, GA), Apollon (Philadelphia, PA) and Cambridge Biotech (Boston, MA)...
Kamal Puri, CSO,
OncoResponse
Kamal Puri is the Chief Scientific Officer at OncoResponse Inc. He has over 25 years of R&D experience in immunology, oncology, and neurobiology. Kamal joined OncoResponse from Celgene, where he led efforts for immunology discovery. Prior to Celgene, he was at Gilead and contributed to the...
Bruce Lyday, Chief Executive Officer,
Coronavax LLC
Bruce Lyday has been a researcher in the fields of virology, immunology, and oncology for over 30 years. He came up with the idea of using the Dengue Fever virus as an anti-cancer agent, leveraging the hyperthermia and intense immune activation against tumors. He received assistance from both the...
Dr Ralph Pantophlet, Associate Professor,
Simon Fraser University
Dr. Pantophlet completed his PhD at the University of Leiden, subsequent postdoctoral training at the Scripps Research Institute, and a one-year fellowship at Research Center Borstel. He began as a tenure track Assistant Professor in the Faculty of Health Sciences (FHS) at Simon Fraser University...
Dr Kathie Seley-Radtke, Professor Chemistry & Biochemistry,
University of Maryland Baltimore County
Dr. Kathie Seley-Radtke is a Professor in the Department of Chemistry & Biochemistry at the University of Maryland, Baltimore County. Her medicinal chemistry research focuses on targeting coronaviruses, filoviruses, flaviviruses among other infectious diseases, using her novel “fleximer”...
Pravin Kaumaya, Professor and Director Vaccine Research,
The Ohio State University Werner Medical Center
Kaumaya is Professor of Medicine in Department of Ob/Gyn at the OSU Wexner Medical Center and the James Comprehensive Cancer Center. Dr Kaumaya is internationally recognized as an expert in the fields of vaccine research with emphasis on peptide vaccines for cancer, viral diseases as well as...
M Javad Aman, President and Chief Scientific Officer,
Integrated BioTherapeutics
Javad Aman has been the President and Chief Scientific Officer (CSO) of Integrated BioTherapeutics, Inc. (IBT), a US biotechnology company focused on the discovery of vaccines and immunotherapeutics for emerging infectious diseases. Since 2007, he has led a group of 40 people working on several...
William Smith, PI/Chief Executive Officer,
Alliance for Multispecialty Research LLC
Dr. William Smith is the Founder, President, and Principal Investigator of VRG and NOCCR, the AMR centers in Knoxville, TN and New Orleans, LA. He is also one of the original founders of AMR. Dr. Smith is board certified in Internal Medicine, Critical Care Medicine, Nephrology and Cardiology. He...
Stephen Albert Johnston, Co-Founder,
CALVIRI
Stephen Albert Johnston is the inventor of Calviri’s central technologies. In addition to Calviri, he has been a founder of Eliance, Inc. (Macrogenics), Synbody Biotechnology and HealthTell (iCx), Inc. He is Director of the Arizona State University Biodesign Institute’s Center for Innovations in...
Lauren V Wood, Chief Medical Officer,
P.D.S. Biotechnology Corp
Dr. Wood joined PDS Biotechnology as Chief Medical Officer in February 2019. She has overall responsibility for clinical development of the novel, immune activating Verrsamuneâ platform product pipeline targeting HPV-related pre-cancer and advanced cancers as well as a broad spectrum of solid...
Max Lataillade, Vice President, Head of Global Research Strategy,
ViiV Healthcare
Max Lataillade VP Head of global Research Strategy, is responsible for global research and development strategy for the HIV pipeline at ViiV Healthcare, the only company 100% dedicated to HIV. He oversees end-to-end R&D activities for all novel HIV pipeline programs designed to address key...
Upendra Marathi, Chief Executive Officer,
7 Hills Pharma LLC
Upendra Marathi, PhD, MBA is the CEO and a co-founder of 7 Hills Pharma. He is an inventor of their first-in-concept technology and a significant investor in the company. He has led the development of three novel pain and cardiovascular drugs, including one recently approved by the FDA. He...
Philip Brouwer, Postdoctoral fellow,
Scripps Research
After obtaining his Masters degree in Pharmaceutical Sciences, Philip pursued his research interest as a graduate student at the Amsterdam University Medical Center. Under the mentorship of Prof. Rogier Sanders, as well as Dr. Neil King at the University of Washington, he worked on the development...
Michael Caldwell, Assoc VP Vaccine Research & Education,
Meharry Medical College
Dr. Caldwell is the Associate Vice President, Vaccine Research & Education at Meharry Medical College in Nashville TN. He leads the emerging partnership between Meharry and Clinical Research Associates of Nashville and is a devoted clinician and teacher. Dr. Caldwell serves as an investigator...
Chardae Foster, Medical Student; Lead, Physician Education & Training Program,
Meharry Medical College
Chardae Foster is a medical student at Meharry Medical College in Nashville, TN. She earned her BS at the University of Tennessee, Knoxville where she majored in Neuroscience in pursuit of a medical career in Neurology. Her passion to become a Neurologist was sparked by her brother who has Epilepsy ...
Maria Karasarides, Vice-President, Head Early Assets & Biomarkers,
Bristol-Myers Squibb
Maria Karasarides, Ph.D. is an Executive Director, ImmunoOncology Development, at Regeneron Pharmaceuticals. Prior to joining Regeneron, Dr. Karasarides was a senior leader in the ImmunoOncology Late Stage Clinical Group at AstraZeneca where she oversaw the clinical strategy and scientific...
Adam Yasgar, Staff Scientist, Biology,
National Center for Advancing Translational Sciences (NCATS)
Adam S. Yasgar received a B.Sc. in chemistry at the George Washington University in 2001. As an undergraduate, he discovered his scientific passion for analytical chemistry through his work using high-performance liquid chromatography/mass spectrometry to separate and identify illegal components in ...
Steven Reed, Chief Executive Officer,
HDT Bio Corp
Steve Reed is the co-founder, President, and CEO of HDT Bio, based in Seattle, USA. His academic appointments include Adjunct Professor of Medicine at Cornell University Medical College Research Professor of Pathobiology at the University of Washington. Dr. Reed received a PhD in Microbiology and...
Dr Kimberly Armstrong, Chief of the Therapeutics Branch in the Influenza and Emerging Infectious Diseases Division,
BARDA
Kimberly Armstrong, Ph.D., MT (ASCP) is the Chief of the Therapeutics Branch in the Influenza and Emerging Infectious Diseases Division at the Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the...
Maria Karasarides, Vice-President, Head Early Assets & Biomarkers,
Bristol-Myers Squibb
Maria Karasarides, Ph.D. is an Executive Director, ImmunoOncology Development, at Regeneron Pharmaceuticals. Prior to joining Regeneron, Dr. Karasarides was a senior leader in the ImmunoOncology Late Stage Clinical Group at AstraZeneca where she oversaw the clinical strategy and scientific...
Kristin DeBord, Acting Deputy Director, Office of Strategy, Policy, Planning & Requirements,
Department of Health and Human Services
Dr. DeBord is the Acting Deputy Assistant Secretary for the Office of Strategy, Policy, Planning, and Requirements (SPPR) within the Administration for Strategic Preparedness and Response (ASPR). She provides leadership and oversight to the office, ensuring ASPR’s operational preparedness and...
Alessandro Sette, Center Head, Division Head, And Professor,,
La Jolla Institute for Allergy and Immunology
Dr. Alessandro Sette has devoted more than 35 years in biotech and academia to understanding and measuring immune responses, and developing disease intervention strategies against cancer, autoimmunity, allergy, and infectious diseases. Dr. Sette’s laboratory is the world leader in the study of the...
Jeffrey Glenn, Professor of Medicine and of Microbiology & Immunology,
Stanford University
Jeffrey Glenn, M.D., Ph.D. is a Professor of Medicine (Division of Gastroenterology & Hepatology) and Microbiology & Immunology at Stanford University School of Medicine, and the Director of the Center for Hepatitis and Liver Tissue Engineering. He also heads a research laboratory focused...
Dr Ilya Goldberg, CSO,
ViQi, Inc.
Dr. Ilya Goldberg has spent the majority of his career at the intersection of biology and imaging, and played a leading role in the development of image informatics and machine learning for bio-medical imaging since the emergence of these fields in the late '90s. At ViQi, Ilya leads development ...
Robert Dillman, Chief Medical Officer,
AIVITA Biomedical, Inc.
Dr. Robert O. Dillman, M.D., is Chief Medical Officer of AIVITA Biomedical. Previously, Dr. Dillman served as Vice President of Oncology at Caladrius Biosciences, Inc. (formerly Neostem, Inc.), a leading development and manufacturing partner to the cell therapy industry. From May 2014 to January...
Dr Andrey Kovalevsky, Senior R&D Scientist,
Oak Ridge National Laboratory (ORNL)
Dr. Andrey Kovalevsky is a structural biologist, biochemist and a Senior R&D Scientist at the Oak Ridge National Laboratory. Dr. Kovalevsky studied organic chemistry and chemical crystallography at Kharkiv State University, Kharkiv, Ukraine, receiving M.Sc. degree with Honors. He received his...
Dr Abhishek Dutta, Assistant Professor,
University of Connecticut
Dr. Dutta is a Professor and Researcher with sustained international recognition who has risen to the top of his field of endeavor, that being in cybernetics and systems medicine. Dr. Dutta joined the University of Connecticut as an Assistant Professor, a tenure-track position, in August 2016 and...
Arthur Young, President And Founder,
InvVax Inc
Dr. Arthur Young did his undergraduate studies at the University of California, Berkeley, majoring in Biology with an emphasis in Immunology, and working under Dr. Nilabh Shastri in the field of antigen processing. He went on to a brief stint in Dr. Ren Sun's lab at the University of...
Karin Jooss, CSO,
Gritstone bio
Karin Jooss, Ph.D., is the head of research and development. She had most recently served as the executive vice president of research and chief scientific officer at Gritstone since April 2016. Prior to Gritstone, from May 2009 to April 2016, Dr. Jooss was the head of cancer immuno-therapeutics in...
Dr Seth Lederman, Co-Founder, Chief Executive Officer & Chairman,
Tonix Pharmaceuticals
Seth Lederman is CEO of Tonix Pharmaceuticals. Prior to Tonix, and his career in Biotech, Dr. Lederman served as tenured Associate Professor at Columbia University and directed basic science research in molecular immunology, infectious diseases and the development of therapeutics for autoimmune...
Dr Xicheng Sun, Vice President, Chemistry & Manufacturing,
Crestone, Inc.
Xicheng Sun, Ph.D. Vice President, Chemistry & Manufacturing at Crestone In. Prior to his current appointment, Dr Sun was an executive director of chemistry and CFTR modulator team leader at N30 Pharmaceuticals, overseeing internal and external activities from medicinal chemistry, chemical...
Iris Grossman, Chief Strategy Officer,
Eleven Therapeutics
On the leading edge of Personalized Medicine & Data Analytics, Dr Grossman spent the last 20 years leading R&D functions in Big Pharma and as Chief Science Officer of small start-ups, marrying between hardcore science, cutting-edge technologies, corporate strategy, fund-raising and...
Dr Takeki Uehara, Corporate Officer, Senior Vice President, Drug Development and Regulatory Science Division,
Shionogi & Co., Ltd.
Dr. Takeki Uehara received his DVM degree at the Department of Veterinary Medicine, Faculty of Agriculture, Tokyo University of Agriculture and Technology, Japan, in 2002. After his graduation, he joined Shionogi & Co., Ltd. as a research scientist. In 2008 he received his PhD degree of...
Dushyant Varshney, EVP & Chief Technology Officer,
Arcturus Therapeutics
Dushyant B. Varshney, Ph.D., is the Executive Vice President & Chief Technology Officer. He is responsible for Global CMC, Technical Operations & Quality, including technology innovation, product development, manufacturing, technology transfer and commercialization of Drug Substance and...
Dr Dale Christensen, Head of Clinical Development,
TFF Pharmaceuticals
Since the formation of TFF Pharmaceuticals, Dr. Christensen has successfully translated three programs from concept to Phase 1 clinical trials and leads the non-clinical and clinical development activities for TFFP. He is a biotech executive and consultant with over 25 years of R&D experience...
Dr Felix Frueh, CSO and Co-Founder,
Selva Therapeutics, Inc.
Dr. Frueh was previously CSO at Human Longevity, Inc. He was the President of the Medco Research Institute and the first Associate Director for Genomics at FDA. In addition, he held executive positions in multiple biotechnology companies and serves on the Boards of several biotechnology...
Jacob Glanville, Chief Executive Officer,
Centivax
Jacob Glanville is an serial entrepreneur, and computational immuno-engineer. He built and sold his first company Distributed Bio from founding in March of 2012 to a 104M dollar sale to Charles River Laboratories in December of 2020. During that period, he developed the core business model, the...
Jiang Zhu, Associate Professor Tenure Department of Integrative Structural and Computational Biology,
The Scripps Research Institute
Trained as a biophysicist, Jiang conducts research in microbiology, immunology, and vaccinology. His laboratory at Scripps Research is developing single-component, multilayered, self-assembling protein nanoparticle (SApNP) vaccines for viral and non-viral pathogens. They currently work on...
Dr Diego Wyszynski, Chief Executive Officer,
Pregistry
Dr. Wyszynski’s main area of expertise is the assessment of drug and vaccine safety from observational data, with a special emphasis in the analysis of patterns of use and safety of drugs and vaccines during pregnancy. He received his medical degree from the University of Buenos Aires and Master...
Dr Liangfang Zhang, Professor of Nanoengineering,
University of California San Diego
Dr. Liangfang Zhang is Joan and Irwin Jacobs Chancellor Professor of Nanoengineering and Bioengineering and Director of Chemical Engineering Program at the University of California San Diego. Dr. Zhang received his B.E. and M.S. degrees in Chemical Engineering from Tsinghua University, and his...
Michael Salgaller, Supervisor, Invention Development And Marketing Unit,
National Cancer Institute - NIH
Experienced biopharma and life sciences senior manager with strong and successful background in technology development, entrepreneurship, business development, strategic planning, clinical and medical affairs, R&D, and capital formation.
Jaione Maiz, Principal,
Anzu Partners
Dr. Jaione Maiz is a Principal at Anzu Partners with a focus on investing at the intersections of life science and innovative technology. She also supports portfolio companies in business development, strategy, and product development. Prior to Anzu, Jaione was a Director of Business Development at ...
Michael Mowatt, Director, Technology Transfer And Intellectual Property Office,
National Institute of Health - NIAID
Since 2001 Dr. Mowatt has directed the technology transfer program at the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH). His staff of fifty talented and experienced professionals support of the mission of NIAID by facilitating...
Taylor Sexton, Executive Director, Medical Countermeasures Coalition,
Todd Strategy Group
Taylor joined Todd Strategy Group in 2021 after serving as a Senior Advisor to the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services. He served in this role through two administrations and the COVID-19 pandemic. He also maintained his...
Dr Amy Jenkins, Program Manager,
D.A.R.P.A.
Dr. Amy Jenkins joined DARPA as a Program Manager in June 2019. Her interests include the development of platforms for combatting infectious disease threats as well as novel manufacturing methods to enable rapid response. Prior to joining DARPA as a PM, Dr. Jenkins was a Senior Scientist at...
Dr Andrew Vaillant, Chief Scientific Officer,
Replicor Inc.
Dr. Vaillant is the Chief Scientific Officer at Replicor Inc. He has more than 20 years of experience in the fields of nucleic acid chemistry, virology and drug development and is the discoverer of Replicor’s nucleic acid polymer (NAP) technology. Dr. Vaillant has authored numerous primary...
Kevin Killeen, Chief Scientific Officer,
Matrivax R & D Corp
Dr. Killeen joined Matrivax as Chief Scientific Officer in 2009. He has extensive training in the fields of vaccinology, molecular biology, microbiology, protein chemistry, and immunology. Dr Killeen’s experience includes identifying and leading the in-licensing effort of the rotavirus vaccine...
Barry Datlof, Chief, Business Development and Commercialization,
U.S. Army Medical Research and Development Command
Mr. Datlof is the Chief, Business Development and Commercialization in the Office of Medical Technology Transfer at the U.S. Army Medical Research and Materiel Command. He has commercialized biomedical and IT technologies in the university, nonprofit, for-profit, and government sectors. He owns...
Madduri Srinivasarao, Vice President, Research and Development,
Eradivir, Inc.
Dr. Madduri Srinivasarao is currently the Vice President, Research & Development at Eradivir, Inc. He received his PhD in chemistry from Purdue University in the field of total synthesis of natural products. He then Joined the research lab of Professor Philip Low at Purdue University where he...
Terrence Stull, President,
BacVax
Terrence L. Stull, M.D., is President of BacVax. He is responsible for the administrative and scientific direction of BacVax’s development of Bacterial Vaccine Polypeptides. His education and training include his M.D. from the University of Birmingham in Alabama, residency training at Stanford, and ...
Len Yaffe, Hedge Fund Manager,
Stoc*Doc Partners
Len Yaffe was the first MD to transition to Wall Street as an analyst many decades ago. He worked primarily at Montgomery Securities in San Francisco, and was recognized as a top analyst in pharmaceuticals, medical devices and drug distribution. He was early in recognizing the impact of intraocular ...
Keith Rubin, Chief Executive Officer,
ILiAD Biotechnologies, LLC
Keith Rubin, M.D. is Founder and CEO of ILiAD Biotechnologies and serves on the Executive Board. Prior to ILiAD, Dr. Rubin founded Seedlings Life Science Ventures, a medical technology company that has successfully developed and advanced multiple patented technologies including the out-license of...
Stephen Albert Johnston, Co-Founder,
CALVIRI
Stephen Albert Johnston is the inventor of Calviri’s central technologies. In addition to Calviri, he has been a founder of Eliance, Inc. (Macrogenics), Synbody Biotechnology and HealthTell (iCx), Inc. He is Director of the Arizona State University Biodesign Institute’s Center for Innovations in...
Sam Lee, President,
Cocrystal Pharma, Inc.
Sam Lee, Ph.D., is President, Interim Co-CEO and co-founder of Cocrystal Pharma Inc., Bothell, Washington, founded in 2007. Cocrystal Pharma Inc. (NASDAQ: COCP) is developing novel small molecule antivirals for the treatment of COVID-19, Influenza, Norovirus, and Hepatitis C. He served on the...
James Wassil, Chief Operating Officer,
Vaxcyte
Jim brings extensive experience in the development and commercialization of vaccines having spent the past three decades in positions of increasing responsibility in the vaccine divisions of Merck, Novartis, and Pfizer. He was responsible for the development and launch of Menveo, the meningococcal...
Dr Seth Lederman, Co-Founder, Chief Executive Officer & Chairman,
Tonix Pharmaceuticals
Seth Lederman is CEO of Tonix Pharmaceuticals. Prior to Tonix, and his career in Biotech, Dr. Lederman served as tenured Associate Professor at Columbia University and directed basic science research in molecular immunology, infectious diseases and the development of therapeutics for autoimmune...
M Javad Aman, President and Chief Scientific Officer,
Integrated BioTherapeutics
Javad Aman has been the President and Chief Scientific Officer (CSO) of Integrated BioTherapeutics, Inc. (IBT), a US biotechnology company focused on the discovery of vaccines and immunotherapeutics for emerging infectious diseases. Since 2007, he has led a group of 40 people working on several...
Dr Andrew Vaillant, Chief Scientific Officer,
Replicor Inc.
Dr. Vaillant is the Chief Scientific Officer at Replicor Inc. He has more than 20 years of experience in the fields of nucleic acid chemistry, virology and drug development and is the discoverer of Replicor’s nucleic acid polymer (NAP) technology. Dr. Vaillant has authored numerous primary...
Dr Aeron Hurt, Principal Global Medical Science Director, Influenza and COVID-19,
Roche
Dr. Aeron Hurt is the Principal Global Medical Director, for both COVID-19 and Influenza at Roche, Basel, Switzerland. Aeron was previously Head of the Antiviral Susceptibility Analysis Surveillance Unit and Research group at the WHO Collaborating Centre for Reference and Research on...
Jeffrey Glenn, Professor of Medicine and of Microbiology & Immunology,
Stanford University
Jeffrey Glenn, M.D., Ph.D. is a Professor of Medicine (Division of Gastroenterology & Hepatology) and Microbiology & Immunology at Stanford University School of Medicine, and the Director of the Center for Hepatitis and Liver Tissue Engineering. He also heads a research laboratory focused...
Pravin Kaumaya, Professor and Director Vaccine Research,
The Ohio State University Werner Medical Center
Kaumaya is Professor of Medicine in Department of Ob/Gyn at the OSU Wexner Medical Center and the James Comprehensive Cancer Center. Dr Kaumaya is internationally recognized as an expert in the fields of vaccine research with emphasis on peptide vaccines for cancer, viral diseases as well as...
